BSD Medical Corporation (AMEX:BSM) develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD Medical is also making major progress in the application of its technology for other therapies. Microwave and RF hyperthermia therapy has been shown to substantially improve local control of cancer, tumor response and survival rates when added to radiation treatments. In phase III clinical trials where hyperthermia was combined with radiation therapy, hyperthermia improved 2-year local control of melanoma from 28% to 46%, complete response for recurrent breast cancer from 38% to 60%, 2-year survival for glioblastoma (brain cancer) from 15% to 31% and complete response for advanced cervical cancer from 57% to 83%, as compared to the use of radiation therapy alone. BSD Medical Corporation was the first company to obtain PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for a hyperthermia cancer therapy system and the first company to obtain Investigational Device Exemption (IDE) approval from the FDA for thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH). BSD has sold and manufactured over 200 hyperthermia systems installed throughout the world. Since its founding, BSD Medical has invested over $20 million in development of technology for hyperthermia treatment, and substantially greater funding has been provided for the clinical trials by the U.S. National Institutes of Health (NIH) and European governments.
This article uses content from
http://www.AboutUs.org
